NDA 19693, held by Lilly. Indecainide Hydrochloride.
As of Nov 13, 2026, NDA 19693 (Decabid), held by Lilly, was first approved by FDA on Dec 29, 1989, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 29, 1989 | Original applicationNew molecular entity · Standard review | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| DecabidEQ 50MG BASE · tablet, extended release;oral | Indecainide Hydrochloride | Discontinued |
| DecabidEQ 75MG BASE · tablet, extended release;oral | Indecainide Hydrochloride | Discontinued |
| DecabidEQ 100MG BASE · tablet, extended release;oral | Indecainide Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters